PT-141 + Oxytocin for Women: The Trials Behind Each Component, and the Cautions

PT-141 + Oxytocin is a 5 mL vial holding 10 mg PT-141 and 5 mg oxytocin, in a fixed ratio. The rationale prescribers give is that PT-141 is aimed at desire and initiation while oxytocin is aimed at the orgasmic phase and closeness afterwards. That is a rationale, not a finding. Neither component raises oestrogen or testosterone, and neither acts on blood flow.

RECONNECT: the two phase 3 trials

Two identical 24-week, randomised, double-blind, placebo-controlled trials, published together in Obstetrics & Gynecology in 2019, enrolled 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder. They self-injected 1.75 mg bremelanotide or placebo as needed.

Those are modest absolute differences, and they supported FDA approval of a bremelanotide product on 21 June 2019. Low desire explained by a medical or psychiatric condition, a relationship problem or a medication was excluded. A 52-week open-label extension followed 684 women; no new safety signals emerged, and most used it two to three times a month.

How PT-141 is described to work

Animal studies, reviewed in CNS Spectrums in 2022, suggest bremelanotide activates MC4 receptors in the medial preoptic area of the hypothalamus and increases dopamine release there. The approved label states the mechanism for desire is unknown, so that is the leading explanation, not a settled one.

• The combination. No study has tested PT-141 and oxytocin together.
• The compounded dose. RECONNECT used 1.75 mg by autoinjector; a combination dose is 0.2 mg PT-141 with 0.1 mg oxytocin.
• Injected oxytocin. Every oxytocin study used a nasal spray measured in IU, which cannot be converted to milligrams on a vial.
• Postmenopausal women and PT-141. Both RECONNECT trials enrolled premenopausal women, and the approved product is not indicated after menopause.
• Arousal, lubrication or orgasm as primary PT-141 outcomes. The phase 3 trials measured desire and distress.
• Long-term safety of oxytocin injection at these doses. Those studies have not been run.

There is no evidence that the combination is better for women than PT-141 alone. If desire is the whole problem, PT-141 alone is the more targeted prescription. If the interest is closeness or the post-orgasmic phase with no complaint about desire, oxytocin alone avoids PT-141's nausea and blood-pressure profile. How the two compare is in PT-141 vs oxytocin, and kisspeptin, which acts on the reproductive hormone axis, is compared in kisspeptin vs oxytocin.

The combination's side effects are dominated by its PT-141 component. These rates are from the phase 3 trials of bremelanotide at 1.75 mg.

There are no systematic safety data for oxytocin at the small subcutaneous doses in this vial. Never take a second dose within 24 hours. The approved bremelanotide label instructs stopping after eight weeks if a woman reports no improvement; if nothing has changed after two months used as directed, tell your physician rather than reaching for more doses. More is in PT-141 side effects and oxytocin side effects.

Bremelanotide is the active ingredient of a product the FDA approved on 21 June 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Oxytocin is the active ingredient of an approved hospital injection for labour and postpartum bleeding; intimacy is not an approved use. Both may be compounded by a licensed 503A pharmacy as components of approved products, and neither was ever in Category 2. The combination vial is a different formulation prepared to an individual prescription, has not been reviewed by the FDA, and is not FDA approved.

The vial holds 50 doses at 0.10 mL; because it is used on occasions, the beyond-use date on the label governs when it is replaced. The price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials ship ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Lot test results are at /quality/lab-results. Your physician sets your directions after reviewing your intake, and they are printed on the vial. Dosing detail is in PT-141 + Oxytocin dosage, and what each component's research looked at is in PT-141 + Oxytocin benefits.

It cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications, blood pressure, pregnancy, breastfeeding and contraception, and what has changed about desire or intimacy.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Step by step: how to get PT-141 + Oxytocin prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.